Piramal Pharma Ltd.
NSE: PPLPHARMAPiramal Pharma Ltd.: A 30-second snapshot
PPLPHARMA trades at ₹195.68, up 22.07% over the past three months but roughly flat over the past year (-3.24%), sitting within 0.4% of its nearest resistance level of ₹196.44 and 7.04% off its 52-week high. Trailing ROE stands at -4% and net margin at -3.67%, with a June-quarter consolidated net loss of ₹693.9 million, against a forward PE of 46.42. Mean analyst rating is 1.45 across 11 analysts (1-5 scale, lower = more constructive).
P/E
—
Forward P/E
46.4
ROE
-4.0%
Debt / Equity
69.98
Profit Margin
-3.7%
Div. Yield
+0.1%
5Y ROE > 15%
0/5
5Y FCF > 0
3/5
Quality
45/100
News
7 headlines · 2 positive · 4 negative
Piramal Pharma June-Quarter Consol Net Loss 693.9 Million Rupees - TradingView
TradingView
Piramal Pharma's FY2026 Annual Report showcases global scale, innovation-led growth and sustainability milestones - Plataforma Media
Plataforma Media
Piramal Pharma Gujarat Operations: मुसळधार पावसामुळे तात्पुरता खोळंबा - Whalesbook
Whalesbook
Piramal Pharma Share: குஜராத்தில் கனமழையால் உற்பத்தி நிறுத்தம்! ஊழியர்கள் பாதுகாப்பு உறுதி - Whalesbook
Whalesbook
Stocks to buy: Piramal Pharma, HSCL among 3 top bets by Choice Broking - Business Standard
Business Standard
Recent context
- ·June-quarter (Q1 FY27) results showed a consolidated net loss of ₹693.9 million, reported July 29, 2026 (TradingView).
- ·Coverage on July 24, 2026 (Whalesbook) described a temporary production halt at the company's Gujarat operations due to heavy monsoon rainfall.
- ·Choice Broking listed the stock among its "top bets" in a July 6, 2026 report (Business Standard); separate coverage on July 7, 2026 highlighted the FY2026 annual report's scale and sustainability disclosures.
Strengths
- +3-month price gain of 22.07%, with the stock trading above both its 50-DMA (₹172.36) and 200-DMA (₹170.03).
- +Mean analyst rating of 1.45 across 11 analysts (1-5 scale, lower = more constructive).
- +Free cash flow positive in 3 of the years covered by available persistence data, despite negative trailing ROE.
- +Dividend yield of 0.08% maintained alongside a flat debt trend per available data.
Weaknesses
- −Trailing ROE of -4% and net profit margin of -3.67%, with zero years of ROE above 15% on record and 5-year revenue growth of -0.1%; June-quarter consolidated net loss reported at ₹693.9 million.
- −Debt-to-equity of approximately 70% (0.70x) carried against negative trailing profitability, with a flat debt trend and consistency/quality scores of 28.
- −Ranks 5th of 6 peers on ROE and 4th of 6 on quality score within the Pharma sector (quality score 28 vs Sun Pharma 56, Apollo Hospitals 44).
- −Current price is within 0.4% of the nearest resistance level (₹196.44) after a steep 3-month rally, with RSI at 69.45 approaching the overbought threshold.
Open questions
- ?Does the forward PE of 46.42 reflect a credible near-term path back to profitability, or does it depend on assumptions not yet visible in trailing ROE and margin data?
- ?What explains the gap between the company's negative trailing ROE (-4%), its 5th-of-6 sector ranking, and the constructive 1.45 mean analyst rating?
- ?Is the temporary Gujarat production disruption reported in July 2026 likely to show up in near-term margin or revenue figures, and how has the company addressed similar disruptions historically?
- ?How does a flat debt trend at roughly 70% debt-to-equity interact with continued net losses over successive quarters, and what would a sustained return to positive ROE look like?
Peer comparison: Pharma
Ranks 4 of 6 on quality| Symbol | Name | P/E | ROE | Quality |
|---|---|---|---|---|
| PPLPHARMA | Piramal Pharma Ltd.You're viewing | — | -4.0% | 28 |
| Industry avg | across 5 peers | 49.4 | +14.8% | 34 |
| SUNPHARMA | Sun Pharmaceutical Industries Ltd. | 41.6 | +14.7% | 56 |
| APOLLOHOSP | Apollo Hospitals Enterprise Ltd. | 66.0 | +21.5% | 44 |
| MAXHEALTH | Max Healthcare Institute Ltd. | 75.1 | +14.3% | 37 |
| CIPLA | Cipla Ltd. | 35.3 | — | 28 |
| DRREDDY | Dr. Reddy's Laboratories Ltd. | 28.7 | +8.8% | 4 |
Technical state
Current price
₹195.68
SMA 50
₹172.36
SMA 200
₹170.03
RSI (14)
69.5 (neutral)
From 52w high
-7.0%
1Y return
-3.2%
3M return
+22.1%
50-DMA
Above
200-DMA
Above
Algorithmic support levels
Algorithmic resistance levels
Risk flags
- highTrailing ROE of -4% and net profit margin of -3.67%, with zero years of ROE above 15% on record and 5-year revenue growth of -0.1%; a consolidated net loss of ₹693.9 million was reported for the June quarter (TradingView, July 29, 2026).
- mediumDebt-to-equity of approximately 70% (0.70x) is carried against negative trailing profitability, with a flat debt trend and consistency/quality scores of 28, indicating leverage is currently unsupported by operating returns.
- mediumRanks 5th of 6 peers on ROE and 4th of 6 on quality score within the Pharma sector (quality score 28 vs Sun Pharma 56, Apollo Hospitals 44).
- lowCurrent price (₹195.68) sits within 0.4% of the nearest resistance level (₹196.44) after a 22.07% three-month rally, with RSI at 69.45 approaching the overbought threshold even though the 1-year return remains modestly negative (-3.24%).
Cross-section contradictions
- Forward PE of 46.42 prices in a substantial earnings recovery, yet trailing ROE (-4%) and margin (-3.67%) show current operating losses with zero years of ROE above 15% on record.
- Mean analyst rating of 1.45 across 11 analysts (1-5 scale, lower = more constructive) sits at the constructive end, despite trailing profitability remaining negative and the stock ranking 5th of 6 sector peers on ROE.
- News sentiment for the covered period is net negative (4 negative vs 2 positive articles), yet the stock gained 22.07% over the past 3 months and trades near its nearest resistance level.
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.
Fundamentals & technicals: refreshed 11 Aug 2026 · refreshed daily at 01:00 IST
AI synthesis (narrative, snapshot, strengths/weaknesses, peer ranking): generated 30 Jul 2026 · rotates through NIFTY 500 every ~5 days